Allowing today’s children and adolescents to become tomorrow’s adult role models Our Paediatric Research Hub allows us to promote research in the fields of paediatrics and adolescence. In doing so, it highlights the centre’s vast expertise while uniting efforts and capabilities in order to undertake global change initiatives that allow us to achieve the objectives agreed upon by the entire community of professionals who participate in paediatric and adolescence research at the Vall d'Hebron Campus. The Hub in figures 5 5 Research groups focusing exclusively on paediatrics 26 26 PIs focusing exclusively on paediatrics 141 141 Ongoing paediatric clinical trials 53 53 Ongoing competitive paediatric projects 258 258 Publications 1,727 2K Impact factor (total) 7 7 Impact Factor (average) 30 30 Of all the VHIR’s groups participate in paediatric research From research to healthcare Mission: To promote, develop and transfer the paediatric research work undertaken at Vall d'Hebron University Hospital. Through excellence in our research work, we improve the health and quality of life of children and adolescents. Vision: We want Vall d'Hebron’s paediatric research work to become a global benchmark which has a positive impact on the health and quality of life of paediatric patients and society in general. Strategic lines Pediatric clinical trials As leaders in research, Vall d'Hebron Research Institute are involved in many clinical trials to children and adolescents. In this list you will be able to consult the pediatric clinical trials in which they are working, as well as the phase in which it is and if there has active recruitment. See clinical trials Organization chart Documentation of strategic lines Organization and structure Clinical Trials and Advanced Therapies Training, mentoring and research promotion Innovation and knowledge transfer Collaboration, reference networks and fundraising Active patients participation Today Related news Biomarkers gain prominence in paediatric cancer clinical trials A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress. Identified one of the mechanisms involved in the progression of Dent's disease Researchers at the VHIR have carried out a study showing that the ClC-5 protein regulates collagen levels through the β-catenin pathway and lysosomal degradation. New therapeutic target for an aggressive childhood cancer affecting the muscles The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models. See more